NEW YORK (GenomeWeb) – Swiss diagnostics firm ProteoMedix said today that it has closed a CHF 5 million ($5.2 million) equity financing round.

The company said it plans to use the funds to obtain CE-IVD marking for its lead product, a proteomic test for diagnosing prostate cancer, as well as to collect more clinical data. It also plans to develop an additional test for prostate cancer prognosis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Sponsored by

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.